Company profile: RedPath Integrated Pathology
1.1 - Company Overview
Company description
- Provider of reference laboratory services and oncology case support, offering PathFinderTG, a testing platform for resolving diagnoses from the original pathology specimen, serving pathologists, clinicians, and patients.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to RedPath Integrated Pathology
Grey Wolf Therapeutics
HQ: United Kingdom
Website
- Description: Provider of antigen modulation therapies that control T cell activation by modulating antigen presentation. Offers ERAP1 and ERAP2 inhibition to generate and upregulate cancer antigens, MHCI-directed therapies to identify novel antigens, and GRWD5769, a selective ERAP1 inhibitor in EMITT-1, an adaptive Phase 1/2 clinical trial assessing monotherapy and combinations with anticancer treatments in solid malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Grey Wolf Therapeutics company profile →
Gadeta
HQ: The Netherlands
Website
- Description: Provider of cancer immunotherapies developed through a technology platform based on combinatorial T Cell receptor exchange (CTE) to create optimized gamma delta (γδ) T-cell receptors (TCRs) with enhanced anti-cancer reactivity, including a new cell-based anti-cancer product called T Cells Engineered.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gadeta company profile →
GEDiCube
HQ: The Netherlands
Website
- Description: Provider of AI/ML multi-omics analytics for biomarker discovery, early cancer detection, and treatment monitoring. Offerings include the GEDi Cube platform leveraging epigenomics, transcriptomics, metabolomics, genomics and clinical data; 2600+ biomarker panels for detection and patient stratification; liquid biopsy diagnostics; an explainable AI engine; and non-toxic therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GEDiCube company profile →
CytomX Therapeutics
HQ: United States
Website
- Description: Provider of proteolytically activated Probody therapeutics designed to activate only in cancer via tumor-specific proteases, minimizing activity in healthy tissue. Pipeline includes CX-904, a T-cell-engaging bispecific Probody targeting EGFR and CD3 in Phase 1 for advanced solid tumors; CX-2051, a conditionally activated EpCAM-targeting antibody-drug conjugate; and CX-801, an interferon alpha-2b Probody.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CytomX Therapeutics company profile →
Tesaro
HQ: United States
Website
- Description: Provider of oncology-focused biopharmaceutical solutions dedicated to improving the lives of cancer patients, leveraging management expertise to identify, acquire and develop promising drug candidates and to commercialize safer, more effective cancer therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tesaro company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for RedPath Integrated Pathology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to RedPath Integrated Pathology
2.2 - Growth funds investing in similar companies to RedPath Integrated Pathology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for RedPath Integrated Pathology
4.2 - Public trading comparable groups for RedPath Integrated Pathology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →